Tag: Sanofi

Sanofi Raised 2019 Outlook on the Back of Solid Growth in Q2

Sanofi raised its 2019 outlook on the back of second-quarter results lifted by double-digit growth at its vaccines and rare diseases businesses. Sanofi Chief Executive Officer, Olivier Brandicourt,...

Sanofi Acquired from Roche Exclusive OTC Rights to Tamiflu® in the U.S.

Sanofi signed an agreement with Roche for the exclusive over-the-counter (OTC) rights to Tamiflu® for the prevention and treatment of influenza or flu in the US. Under the terms of the agreement, San...

Opiant Agreed with Sanofi on Manufacturing OPNT004 for Treatment of Acute Cannabinoid Overdose

deal
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced that it has signed an agreement with Sanofi to manufacture Opiant’s in...

FDA to Review BLA from Sanofi for Isatuximab

The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for isatuximab from Sanofi for the treatment of patients with relapsed/refractory multiple m...

FDA to Review Sanofi’s MenQuadfi

The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Sanofi’s MenQuadfiTM Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Con...

Sanofi to Cut 466 Jobs as Part of R&D Reorganization

Sanofi
Sanofi said a reorganization of its research and development operation in Germany and France would result in 466 job cuts in the two countries. In an emailed statement, a spokesman with the French ...

Positive Phase 2 Results for IL-33 Antibody Announced by Sanofi and Regeneron

clinical-trial
Sanofi and Regeneron Pharmaceuticals, Inc. announced that a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in...

Sanofi and Google To Establish New Virtual Innovation Lab

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data...

Sanofi Appointed New CEO

At its meeting on June 6th of 2019, Sanofi’s Board of Directors unanimously appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt who has decided to retire. ...

Sanofi Diabetes Treatment Phase 3 Results Showed Significant Reduction in Blood Sugar Levels

In a Phase 3 study1 evaluating adults with type 2 diabetes inadequately controlled by GLP-1 receptor agonist (GLP-1 RA) treatments, Soliqua® /Suliqua®2 (insulin glargine 100 Units/mL and lixisenatide)...

Sanofi vs Amgen Litigations over Praluent Patents in Germany

Germany’s highest civil court on Tuesday rejected French drugmaker Sanofi’s bid to fend off a legal challenge by U.S. rival Amgen against Sanofi’s cholesterol drug Praluent. In the latest setback f...

Sanofi Enters into Strategic Partnership with Enable Injections

Enable Injections, Inc., a company developing and manufacturing advanced wearable infusion devices for combination products, announced it has entered into a multi-product development agreement with Sa...

Nanolek to Complete Sanofi Vaccine Localization by 2022

nanolek
Nanolek plans to launch the full-cycle production of a 5-in-1 infant vaccine under a technology transfer project with Sanofi Pasteur (France) by 2022. The first phase in the project to localize the...

Cegedim Announced Innovative Collaboration with Sanofi

sanofi
Cegedim has announced that it is set to engage in an innovative collaboration on Real World Data for healthcare improvement in Europe with Sanofi. The company has announced that it will provide San...

Regeneron and Sanofi to Publish Updated Libtayo Data

cancer treatment
Regeneron Pharmaceuticals, Inc. and Sanofi announced that positive updated data for Libtayo® (cemiplimab-rwlc) in locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) will be share...

Sanofi Dupixent Gained EU Approval

Sanofi and Regeneron’s Dupixent will now enter the asthma market in Europe, the new expansion confirming its blockbuster profile. The dual IL-4 and IL-13 inhibitor has just gained approval for the ...